Evidence map›Paper›PMID 42445394›Full record

ArticleTranslational cancer research2026

Ailanthone as a novel AKT1 inhibitor that induces mitochondrial apoptosis and exerts anti-tumor activity in cervical cancer.

Shaofeng Huang, Yanlun Song, Yun Zhao, Xin Zhang, Yannan Jiao, Jin Zhang, Yuehua Huang, Junli Wang, Haimei Qin, Fenglian Yang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Shaofeng Huang *Department of Blood Transfusion, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise China.
Yanlun Song *Key Laboratory of Research on Clinical Molecular Diagnosis for High Incidence Diseases in Western Guangxi of Guangxi Higher Education Institutions, Baise, China.
Yun Zhao *Graduate School, Youjiang Medical University for Nationalities, Baise, China.
Xin ZhangDepartment of Blood Transfusion, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise China.
Yannan JiaoGraduate School, Youjiang Medical University for Nationalities, Baise, China.
Jin ZhangGraduate School, Youjiang Medical University for Nationalities, Baise, China.
Yuehua HuangDepartment of Blood Transfusion, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise China.
Junli WangKey Laboratory of Research on Clinical Molecular Diagnosis for High Incidence Diseases in Western Guangxi of Guangxi Higher Education Institutions, Baise, China.
Haimei QinKey Laboratory of Research on Clinical Molecular Diagnosis for High Incidence Diseases in Western Guangxi of Guangxi Higher Education Institutions, Baise, China.
Fenglian YangGraduate School, Youjiang Medical University for Nationalities, Baise, China.
Rong WangDepartment of Blood Transfusion, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: As a significant global burden on women's health, cervical cancer necessitates the exploration of novel therapeutic strategies driven by the limitations inherent in the current treatment options. Ailanthone (AIL), a natural compound derived from Methods: We evaluated the antitumor activity of AIL in cervical cancer through a series of Results: The Conclusions: Our findings from the cervical cancer cell model indicate that the anti-tumor effect of AIL against cervical cancer may be dependent on AKT1 protein regulation and intracellular apoptotic pathway activation.

Indexed as

Ailanthone (AIL)AKT1apoptosiscervical cancersignaling pathway

Identifiers

PMID42445394
PMCPMC13357064

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.